NCT05252468View on ClinicalTrials.gov

COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

NACompletedINTERVENTIONAL
Enrollment

693

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

November 2, 2021

Study Completion Date

December 2, 2021

Conditions
COVID-19Upper Respiratory Tract Infections
Interventions
DEVICE

TaffiX™

Personal nasal powder spray.

Trial Locations (1)

Unknown

Diagnostics and Consultation Center Convex Ltd, Sofia

Sponsors

Lead Sponsor

Nasus Pharma
All Listed Sponsors
lead

Nasus Pharma

INDUSTRY

NCT05252468 - COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19). | Biotech Hunter | Biotech Hunter